| 20.01 0 (0%) | 10-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 23.37 | 1-year : | 27.29 |
| Resists | First : | 20.01 | Second : | 23.37 |
| Pivot price | 20.01 | |||
| Supports | First : | 19.99 | Second : | 19.97 |
| MAs | MA(5) : | 20.01 | MA(20) : | 20.01 |
| MA(100) : | 15.39  |
MA(250) : | 12.01 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 100 | D(3) : | 100 |
| RSI | RSI(14): 86.8 | |||
| 52-week | High : | 20.28 | Low : | 4.94 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FMTX ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 40 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 20.06 - 20.16 | 20.16 - 20.24 |
| Low: | 19.7 - 19.84 | 19.84 - 19.95 |
| Close: | 19.82 - 20.03 | 20.03 - 20.19 |
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.
Tue, 23 Apr 2024
Forma Therapeutics (FMTX) Sees Hammer Chart Pattern: Time to Buy? - Yahoo Lifestyle UK
Fri, 07 Oct 2022
What is the Market's View on Forma Therapeutics Holdings Inc (FMTX) Stock's Price and Volume Trends Friday? - InvestorsObserver
Thu, 01 Sep 2022
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders - Business Wire
Thu, 30 Jun 2022
Forma Therapeutics Announces Appointment of New Executive Team Members - Business Wire
Tue, 01 Mar 2022
Forma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update - Business Wire
Fri, 11 Jun 2021
Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 91 (%) |
| Shares Short | 1,830 (K) |
| Shares Short P.Month | 2,890 (K) |
| EPS | -3.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.6 % |
| Return on Equity (ttm) | -33.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.66 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -158 (M) |
| Levered Free Cash Flow | -98 (M) |
| PE Ratio | -6.09 |
| PEG Ratio | 0 |
| Price to Book value | 1.74 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|